US20020058696A1 - Chelate compound-containing antibacterial agent for helicobacter pylori - Google Patents

Chelate compound-containing antibacterial agent for helicobacter pylori Download PDF

Info

Publication number
US20020058696A1
US20020058696A1 US09/802,270 US80227001A US2002058696A1 US 20020058696 A1 US20020058696 A1 US 20020058696A1 US 80227001 A US80227001 A US 80227001A US 2002058696 A1 US2002058696 A1 US 2002058696A1
Authority
US
United States
Prior art keywords
helicobacter pylori
antibacterial agent
edta
effective component
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/802,270
Other versions
US6429225B1 (en
Inventor
Toshiro Nagai
Shigeru Oita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inc ADMINSITRATIVE AGENCY
National Institute of Agrobiological Sciences
Original Assignee
DIRECTOR OF NTL INST OF AGROBIOLOGICAL RESOURCES MINISTRY OF AGRICULTURE FORESTRY AND FISHERIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIRECTOR OF NTL INST OF AGROBIOLOGICAL RESOURCES MINISTRY OF AGRICULTURE FORESTRY AND FISHERIES filed Critical DIRECTOR OF NTL INST OF AGROBIOLOGICAL RESOURCES MINISTRY OF AGRICULTURE FORESTRY AND FISHERIES
Assigned to DIRECTOR OF NATIONAL INSTITUTE OF AGROBIOLOGICAL RESOURCES, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES, DIRECTOR GENERAL OF SHIKOKU NATIONAL AGRICULTURAL EXPERIMENT STATION, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES reassignment DIRECTOR OF NATIONAL INSTITUTE OF AGROBIOLOGICAL RESOURCES, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OITA, SHIGERU, NAGAI, TOSHIRO
Assigned to NATIONAL AGRICULTURAL RESEARCH ORGANIZATION reassignment NATIONAL AGRICULTURAL RESEARCH ORGANIZATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DIRECTOR GENERAL OF SHIKOKU NATIONAL AGRICULTURAL EXPERIMENT STATION, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES
Publication of US20020058696A1 publication Critical patent/US20020058696A1/en
Assigned to NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES reassignment NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DIRECTOR OF NATIONAL INSTITUTE OF AGROBIOLOGICAL RESOURCES, MINISTRY OF ARGICULTURE, FORESTRY AND FISHERIES.
Application granted granted Critical
Publication of US6429225B1 publication Critical patent/US6429225B1/en
Assigned to INCORPORATED ADMINSITRATIVE AGENCY reassignment INCORPORATED ADMINSITRATIVE AGENCY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NATIONAL AGRICULTURAL RESEARCH ORGANIZATION
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to an antibacterial agent for Helicobacter pylori , in more detail, to an antibacterial agent for Helicobacter pylori , said agent contains as an effective component a chelate compound, safety of which against human bodies is confirmed.
  • Cure of chronic gastritis and gastric ulcer can be attained by removing the bacterium from stomach by means of administration of antibiotics etc.
  • antibiotics there are some problems concerning appearance of resistant bacteria and side effects.
  • Ethylenediaminetetraacetic acid (hereinafter, sometimes abbreviated to EDTA) has a chelating action on various metal ions and it is known as a reaction inhibitor of enzymes requiring metal ions. Further, EDTA and its metal salts are approved as a food additive in many countries since they have a stabilizing effect for food colors.
  • An object of the invention is to provide an antibacterial agent which has an action for growth inhibition of Helicobacter pylori which participates to occurrence of chronic gastritis and gastric ulcer and in which a highly safe substance is used as an effective component.
  • the inventors of the present invention have searched for antibacterial substances for Helicobacter pylori among of substances accepted as food additives in order to solve the above-mentioned problem, and found that one kind of a chelating agent, EDTA, and its metal salts have an action for growth inhibition of Helicobacter pylori . Thus, the present invention has been completed based on this finding.
  • the present invention relates to an antibacterial agent for Helicobacter pylori , characterized in that at least one substance selected from ethylenediaminetetraacetic acid and its metal salts is contained as an effective component.
  • FIG. 1 is a drawing showing growth rates of Helicobacter pylori in the presence of disodium ethylenediaminetetraacetate having various concentrations
  • FIG. 2 is a drawing showing growth rates of Helicobacter pylori in the presence of iron (III)-sodium ethylenediaminetetraacetate having various concentrations.
  • At least one substance selected from EDTA and its metal salts is used as an effective component of an antibacterial agent for Helicobacter pylori.
  • the metal salt of EDTA any one having an objective antibacterial action may be used.
  • sodium salts, calcium salts and iron salts are preferable.
  • disodium salt, tetrasodium salt and monocalcium disodium salt of EDTA as well as iron (III)-sodium ethylenediaminetetraacetate are preferable.
  • the antibacterial agent according to the invention may be adopted to various forms.
  • EDTA or its metal salt may be used alone or in combination of two or more, if necessary with any suitable adjuvant (such as a vehicle, an extender and a sweetening agent), to make any type of an agent such as a powder, a granule, a solution and a capsule.
  • EDTA and its metal salts may be used by adding them to various foods.
  • the antibacterial agent according to the invention is generally administered orally.
  • Dosages of EDTA and its metal salts may be determined in due consideration of ADI of EDTA, that is, 2.5 mg/kg of weight, as well as these effective amounts for growth inhibition of Helicobacter pylori and a stomach volume (about 1.5 L) of human beings.
  • EDTA and/or its metal salt may be administered for an adult per a day at about 10-500 mg, preferably 10-150 mg, calculated as free EDTA.
  • iron (III)-sodium ethylenediaminetetraacetate it is suitable to administer for an adult per a day at about 60-300 mg, preferably 60-150 mg. If administered in excess, there may be occurred a side effect.
  • administration of EDTA etc. may be carried out at a time or may be divided in several times.
  • the antibacterial agent of the invention may be used in together with other known antibacterial agents for Helicobacter pylori , or also with proton pump inhibitors such as omeprazole or anti-ulcer agents such as bismuth salt.
  • an antibacterial agent for Helicobacter pylori in which highly safe EDTA or its metal salt approved as a food additive in many countries is contained an effective component.
  • Helicobacter pylori (ATCC 43504 strain, purchased from American Type Culture Collection) was cultured with use of a 96-well plate. That is, each 0.1 mL of a medium having a composition of 3% tryptic soy broth (made by Difco), 10% calf serum for tissue culture (made by Wako Pure Chemical) and disodium ethylenediaminetetraacetate (made by Wako Pure Chemical) or iron (III)-sodium ethylenediaminetetraacetate (made by Dojin Molecular Technologies) having various concentrations adjusted to pH 8.0 was poured separately into a 96-well plate.
  • a medium having a composition of 3% tryptic soy broth made by Difco
  • 10% calf serum for tissue culture made by Wako Pure Chemical
  • disodium ethylenediaminetetraacetate made by Wako Pure Chemical
  • iron (III)-sodium ethylenediaminetetraacetate made by Dojin Molecular Technologies
  • the plate After inoculation of Helicobacter pylori , the plate was introduced in a sealed vessel of 2.5 liter volume, into which Anaero Pack-Helico (made by Mitsubishi Gas Chemical), an agent for absorbing oxygen and generating carbon dioxide gas, was also introduced, and cultured for 5 days under an anaerobic condition at 37° C.
  • Anaero Pack-Helico made by Mitsubishi Gas Chemical

Abstract

An antibacterial agent is provided, which has an action for inhibiting growth of Helicobacter pylori participating to occurrence of chronic gastritis and gastric ulcer, and a highly safe substance is used as an effective component therein. An antibacterial agent for Helicobacter pylori is characterized in that at least one substance selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts is contained as an effective component.

Description

    FIELD OF THE INVENTION
  • The present invention relates to an antibacterial agent for [0001] Helicobacter pylori, in more detail, to an antibacterial agent for Helicobacter pylori, said agent contains as an effective component a chelate compound, safety of which against human bodies is confirmed.
    • BACKGROUND OF THE INVENTION
  • Recently, it has been found that [0002] Helicobacter pylori is much participated to occurrence of chronic gastritis and gastric ulcer. In Japan, it is said that about 60 millions people corresponding to an about half of total populations are infected with Helicobacter pylori (Shokunokagaku, Vol. 265, pages 87-99, 2000).
  • Cure of chronic gastritis and gastric ulcer can be attained by removing the bacterium from stomach by means of administration of antibiotics etc. However, there are some cases wherein the bacterium is hard to be removed depending on patients. Further, as to antibiotics, there are some problems concerning appearance of resistant bacteria and side effects. [0003]
  • Further, it is desirable to remove the bacterium not only on people being attacked with a disease but also on people infected with a disease, but it is economically difficult because the number of objectives is quite large. [0004]
  • Therefore, an antibacterial agent for [0005] Helicobacter pylori which is highly safe and which can be taken easily is required.
  • Ethylenediaminetetraacetic acid (hereinafter, sometimes abbreviated to EDTA) has a chelating action on various metal ions and it is known as a reaction inhibitor of enzymes requiring metal ions. Further, EDTA and its metal salts are approved as a food additive in many countries since they have a stabilizing effect for food colors. [0006]
  • Thus, evaluation for safety of EDTA etc. has been already established and an acceptable daily intake (ADI) as a food additive is 2.5 mg/kg of weight (FAO/WHO: Codex Alimentarius Commission, List of additives evaluated for their safety in use in food. CAC/FAL 1-1973, 1973). [0007]
  • Further, in the U.S.A., it is approved that EDTA disodium salt is added to foods within a concentration range of 36-500 ppm (Code of Federal Regulations, Title 21: Food and Drugs, US Government Printing Office, 1988). [0008]
    • SUMMARY OF THE INVENTION
  • An object of the invention is to provide an antibacterial agent which has an action for growth inhibition of [0009] Helicobacter pylori which participates to occurrence of chronic gastritis and gastric ulcer and in which a highly safe substance is used as an effective component.
  • The inventors of the present invention have searched for antibacterial substances for [0010] Helicobacter pylori among of substances accepted as food additives in order to solve the above-mentioned problem, and found that one kind of a chelating agent, EDTA, and its metal salts have an action for growth inhibition of Helicobacter pylori. Thus, the present invention has been completed based on this finding.
  • That is, the present invention relates to an antibacterial agent for [0011] Helicobacter pylori, characterized in that at least one substance selected from ethylenediaminetetraacetic acid and its metal salts is contained as an effective component.
    •  BRIEF DESCRIPTION OF THE DRAWINGS
  • In the accompanying drawings: [0012]
  • FIG. 1 is a drawing showing growth rates of [0013] Helicobacter pylori in the presence of disodium ethylenediaminetetraacetate having various concentrations; and
  • FIG. 2 is a drawing showing growth rates of [0014] Helicobacter pylori in the presence of iron (III)-sodium ethylenediaminetetraacetate having various concentrations.
    • DETAILED DESCRIPTION OF THE INVENTION
  • According to the invention, at least one substance selected from EDTA and its metal salts is used as an effective component of an antibacterial agent for [0015] Helicobacter pylori.
  • As the metal salt of EDTA, any one having an objective antibacterial action may be used. For example, sodium salts, calcium salts and iron salts are preferable. In particular, disodium salt, tetrasodium salt and monocalcium disodium salt of EDTA as well as iron (III)-sodium ethylenediaminetetraacetate are preferable. [0016]
  • The antibacterial agent according to the invention may be adopted to various forms. For example, EDTA or its metal salt may be used alone or in combination of two or more, if necessary with any suitable adjuvant (such as a vehicle, an extender and a sweetening agent), to make any type of an agent such as a powder, a granule, a solution and a capsule. Further, EDTA and its metal salts may be used by adding them to various foods. The antibacterial agent according to the invention is generally administered orally. [0017]
  • Dosages of EDTA and its metal salts may be determined in due consideration of ADI of EDTA, that is, 2.5 mg/kg of weight, as well as these effective amounts for growth inhibition of [0018] Helicobacter pylori and a stomach volume (about 1.5 L) of human beings.
  • In order to inhibit growth of [0019] Helicobacter pylori in stomach, EDTA and/or its metal salt may be administered for an adult per a day at about 10-500 mg, preferably 10-150 mg, calculated as free EDTA. Also, for the case of iron (III)-sodium ethylenediaminetetraacetate, it is suitable to administer for an adult per a day at about 60-300 mg, preferably 60-150 mg. If administered in excess, there may be occurred a side effect. Herein, administration of EDTA etc. may be carried out at a time or may be divided in several times.
  • The antibacterial agent of the invention may be used in together with other known antibacterial agents for [0020] Helicobacter pylori, or also with proton pump inhibitors such as omeprazole or anti-ulcer agents such as bismuth salt.
  • According to the invention, an antibacterial agent for [0021] Helicobacter pylori is provided in which highly safe EDTA or its metal salt approved as a food additive in many countries is contained an effective component.
  • Growth of [0022] Helicobacter pylori present in a digestive system of human beings can be inhibited effectively by administering the antibacterial agent alone or in together with suitable adjuvants or by taking a food containing it. Thus, according to the invention, gastrointestinal disorders reported to be participated to Helicobacter pylori can be prevented and treated effectively.
    • EXAMPLES
  • The invention is illustrated as follows with showing the Example, but the invention is not limited thereto. [0023]
    • Example 1
  • [0024] Helicobacter pylori (ATCC 43504 strain, purchased from American Type Culture Collection) was cultured with use of a 96-well plate. That is, each 0.1 mL of a medium having a composition of 3% tryptic soy broth (made by Difco), 10% calf serum for tissue culture (made by Wako Pure Chemical) and disodium ethylenediaminetetraacetate (made by Wako Pure Chemical) or iron (III)-sodium ethylenediaminetetraacetate (made by Dojin Molecular Technologies) having various concentrations adjusted to pH 8.0 was poured separately into a 96-well plate. After inoculation of Helicobacter pylori, the plate was introduced in a sealed vessel of 2.5 liter volume, into which Anaero Pack-Helico (made by Mitsubishi Gas Chemical), an agent for absorbing oxygen and generating carbon dioxide gas, was also introduced, and cultured for 5 days under an anaerobic condition at 37° C.
  • Growth of [0025] Helicobacter pylori was determined by means of a 96-well plate reader with use of a 540 nm or 595 nm filter. Herein, as a control for absorbance determination, a medium without EDTA was used. Results thereof are shown in FIG. 1 and FIG. 2. In the figures, degree of the growth of Helicobacter pylori depending on concentration of the effective component like EDTA etc. was measured with turbidity, and is shown with the rate against turbidity in growth of Helicobacter pylori in the control medium.
  • From FIG. 1, it is seen that growth of [0026] Helicobacter pylori ATCC 43504 strain is inhibited by means of 0.025-1 mM disodium ethylenediaminetetraacetate. Further, from FIG. 2, it is seen that growth of Helicobacter pylori ATCC 43504 strain is inhibited by means of 0.1-0.5 mM iron (III)-sodium ethylenediaminetetraacetate.
  • Herein, 0.025-1 mM disodium ethylenediaminetetraacetate (molecular weight: 372Da) is converted into 9.3-372 mg/L, which is less than 500 ppm, which is, as described above, upper limit of the concentration approved for food additives in the U.S.A. [0027]
  • Further, since a stomach volume of human being is said as about 1.5 L, growth of [0028] Helicobacter pylori can be inhibited if 14-558 mg (11-438 mg as free EDTA) of disodium ethylenediaminetetraacetate is taken.
  • On the other hand, for the case of iron (III)-sodium ethylenediaminetetraacetate (molecular weight: 421Da), growth of [0029] Helicobacter pylori can be inhibited if 63-316 mg is taken.

Claims (2)

What is claimed is:
1. An antibacterial agent for Helicobacter pylori, comprises containing at least one substance selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts as an effective component.
2. The antibacterial agent for Helicobacter pylori according to claim 1, wherein the metal salt of ethylenediaminetetraacetic acid is disodium ethylenediaminetetraacetate or iron (III)-sodium ethylenediaminetetraacetate.
US09/802,270 2000-11-16 2001-03-08 Chelate compound-containing antibacterial agent for Helicobacter pylori Expired - Fee Related US6429225B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000349003A JP3680081B2 (en) 2000-11-16 2000-11-16 Antibacterial agent for Helicobacter pylori containing chelating agent
JP2000-349003 2000-11-16

Publications (2)

Publication Number Publication Date
US20020058696A1 true US20020058696A1 (en) 2002-05-16
US6429225B1 US6429225B1 (en) 2002-08-06

Family

ID=18822482

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/802,270 Expired - Fee Related US6429225B1 (en) 2000-11-16 2001-03-08 Chelate compound-containing antibacterial agent for Helicobacter pylori

Country Status (8)

Country Link
US (1) US6429225B1 (en)
EP (1) EP1208839B1 (en)
JP (1) JP3680081B2 (en)
KR (1) KR100454112B1 (en)
CN (1) CN1353986A (en)
AU (1) AU758830B2 (en)
CA (1) CA2340545C (en)
DE (1) DE60103835T2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091555A1 (en) * 2001-08-22 2003-05-15 National Agricultural Research Organization Bactericidal composition containing peptide and chelating agent
CN109161491A (en) * 2018-07-27 2019-01-08 菏泽睿智科技开发有限公司 A kind of deep-layer liquid cultural method of helicobacter pylori

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047763A1 (en) * 2001-12-05 2004-03-11 Peter Kite Anti-microbial systems and methods
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
US20050282895A1 (en) * 2004-06-21 2005-12-22 Dosch Michael H Antimicrobial compositions and methods of use thereof
KR101038081B1 (en) * 2008-07-16 2011-06-01 명성테크 주식회사 A prefabricated simplicity water tank
US8685133B2 (en) 2010-12-22 2014-04-01 Scott G. Williams, Llc Chelated compositions and methods of making and using the same
HUP1200394A2 (en) 2012-06-29 2014-02-28 Bata Zrt Dr Bactericidal effect of metal chelate
KR102612453B1 (en) * 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 Anti-infective methods, compositions, and devices
RU2626675C2 (en) * 2015-12-28 2017-07-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Method for gastritis prediction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356932A (en) * 1989-05-22 1994-10-18 Alcon Laboratories, Inc. Methods and compositions for controlling intraocular pressure with transition metal complexes
AU686829B2 (en) * 1994-06-29 1998-02-12 Reckitt Benckiser Healthcare (Uk) Limited Pharmaceutical compositions containing triclosan or derivatives thereof and EDTA or EGTA

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091555A1 (en) * 2001-08-22 2003-05-15 National Agricultural Research Organization Bactericidal composition containing peptide and chelating agent
CN109161491A (en) * 2018-07-27 2019-01-08 菏泽睿智科技开发有限公司 A kind of deep-layer liquid cultural method of helicobacter pylori

Also Published As

Publication number Publication date
KR20020038445A (en) 2002-05-23
KR100454112B1 (en) 2004-10-26
EP1208839B1 (en) 2004-06-16
DE60103835T2 (en) 2005-07-14
EP1208839A1 (en) 2002-05-29
JP3680081B2 (en) 2005-08-10
CN1353986A (en) 2002-06-19
DE60103835D1 (en) 2004-07-22
JP2002154957A (en) 2002-05-28
AU758830B2 (en) 2003-04-03
AU2484701A (en) 2002-05-23
CA2340545C (en) 2007-05-01
CA2340545A1 (en) 2002-05-16
US6429225B1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
EP1917959B1 (en) New medical use of alfa-ketoglutarate
KR101610791B1 (en) New medical applications of alpha-ketoglutarate
EP2712318B1 (en) Composition comprising probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during pharmalogical treatment of gastric hyperacidity
FI114852B (en) Acidified nitrate for use as an antimicrobial agent
US6429225B1 (en) Chelate compound-containing antibacterial agent for Helicobacter pylori
CA1275926C (en) Veterinary composition containing actively absorbed monosaccharide
Silley et al. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system
EP0959878A4 (en) Method for treating renal failure
EP1318804B1 (en) Iron compositions
CA2152693A1 (en) Therapeutic composition for pancreatitis
Wang et al. World-wide clinical experience with norfloxacin: efficacy and safety
Unger et al. SA446, a new orally active converting enzyme inhibitor: antihypertensive action and comparison with captopril in stroke-prone spontaneously hypertensive rats
EP0390574A2 (en) Compositions of phytic acid, and pharmaceutical uses thereof
Poiger et al. Compensation of dietary induced reduction of tetracycline absorption by simultaneous administration of EDTA
Asscher Urinary tract infection
Bayerdörffers et al. Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection
KR100375342B1 (en) A natural antimicrobial agents for the improvement of gastrointestinal disease.
Chow et al. Effects of dietary supplements and methylene blue on urinary calculi
US3055805A (en) Process of treating acidosis with t.h.a.m.
US20230056702A1 (en) Reducing oxygen levels in the gastrointestinal tract
KR102629519B1 (en) Bacillus amyloliquefaciens strain for improving blood levels of TMAO and TMA elevated by high protein and high choline intake
Granados et al. Influence of sulfaguanidine on certain symptoms of vitamin E deficiency in rats
EP0078859A1 (en) An antianaemic agent and a process for producing the same
RU2116038C1 (en) Food additive, method for preparation of products with higher food value, and method for preparation of potable mineralized water
Axon The ascorbic acid story

Legal Events

Date Code Title Description
AS Assignment

Owner name: DIRECTOR OF NATIONAL INSTITUTE OF AGROBIOLOGICAL R

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGAI, TOSHIRO;OITA, SHIGERU;REEL/FRAME:011587/0773;SIGNING DATES FROM 20010228 TO 20010302

Owner name: DIRECTOR GENERAL OF SHIKOKU NATIONAL AGRICULTURAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGAI, TOSHIRO;OITA, SHIGERU;REEL/FRAME:011587/0773;SIGNING DATES FROM 20010228 TO 20010302

AS Assignment

Owner name: NATIONAL AGRICULTURAL RESEARCH ORGANIZATION, JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:DIRECTOR GENERAL OF SHIKOKU NATIONAL AGRICULTURAL EXPERIMENT STATION, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES;REEL/FRAME:012432/0712

Effective date: 20010801

AS Assignment

Owner name: NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES, JAP

Free format text: CHANGE OF NAME;ASSIGNOR:DIRECTOR OF NATIONAL INSTITUTE OF AGROBIOLOGICAL RESOURCES, MINISTRY OF ARGICULTURE, FORESTRY AND FISHERIES.;REEL/FRAME:013098/0030

Effective date: 20020626

AS Assignment

Owner name: INCORPORATED ADMINSITRATIVE AGENCY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NATIONAL AGRICULTURAL RESEARCH ORGANIZATION;REEL/FRAME:014699/0538

Effective date: 20031001

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100806